Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC
Tempus AI Inc Class A common stock TEM
News
Tempus to Report Third Quarter 2026 Financial Results on November 2
Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
Tempus Enters Multiyear Collaboration With Moderna, Merck Aimed at Commercializing Cancer Drug
Tempus Announces Multi-Year Collaboration with Moderna and Merck
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation
Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology
Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
CellCarta Adds Tempus to CDx Commercialization Lab Network
Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications
Tempus Reports Second Quarter 2026 Results
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Tempus AI Shares Up After FDA Clearance for In Vitro Diagnostic Device
United States